Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‐small cell lung cancer: A retrospective cohort study

ABSTRACT: Neoadjuvant immune checkpoint inhibitor (ICI) treatment + chemotherapy has been used for locally advanced non-small cell lung cancer (NSCLC); however, evidence regarding the efficacy of this treatment is insufficient, particularly in Chinese patients. Therefore, the aim of the present study was to evaluate the efficacy and safety of neoadjuvant ICI treatment + chemotherapy compared with neoadjuvant chemotherapy alone for locally advanced NSCLC. For this, 50 patients with locally advanced NSCLC were retrospectively analyzed; of these, 23 patients received pre-operative camrelizumab or sintilimab + chemotherapy (ICI + chemo group) and 27 patients received pre-operative chemotherapy alone (chemo group). The objective response rate (73.9 vs. 44.4%, P=0.035) was superior in the ICI + chemo grou

SUBMITTER: Yang Y 

PROVIDER: S-EPMC10236247 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature